Navigation Links
Questcor Reports Fourth Quarter and Full Year 2012 Results
Date:2/26/2013

th quarter of 2012, the company initiated the expansion of its rheumatology sales force to 55 from 12 rheumatology representatives.
  • Questcor also continued to demonstrate its commitment to returning capital to shareholders, by expanding its common share repurchase program authorization by an additional 5 million shares and adopting a policy to pay a regular quarterly dividend in September 2012. The company repurchased 6.8 million shares in 2012.
  • Following the end of the fourth quarter of 2012:

  • On January 18, 2013, Questcor acquired BioVectra Inc. for an upfront payment of $50.8 million. BioVectra has been Questcor's manufacturing partner for the active pharmaceutical ingredient (API) in Acthar for nearly a decade. The acquisition further secures the manufacturing process trade secrets surrounding Acthar.
  • During the first quarter of 2013, the Medicaid rebate amount for Acthar was reset to the standard basic rebate.
  • On January 28, 2013, Questcor strengthened its management team with the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and development of partnership and acquisition opportunities to leverage Questcor's business model. Over time, such initiatives may include development programs or products complementary to Acthar and the evaluation of potential expansion into ex-US markets.
  • Acthar Label InformationThe product label for Acthar includes 19 FDA-approved indications. Substantially all of the Company's net sales currently result from Acthar prescriptions for the following on-label indications of:

  • Nephrotic Syndrome (NS): "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." NS can result from several underlying conditions, and prescribing physicians indicate that Acthar
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    2. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    3. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    4. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    5. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    6. Questcor Comments on Insurance Policy Bulletin
    7. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    8. Questcor Pharmaceuticals to Present at Investor Conferences in September
    9. Questcor Reports Second Quarter Financial Results
    10. Questcor to Report Second Quarter Results on July 24, 2012
    11. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... Ohio, July 30, 2015 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year. Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior-year period. Adjusted EPS was $2.80 , ...
    (Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
    (Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
    Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
    ... Nov. 3, 2010 DURECT Corporation (Nasdaq: DRRX ... September 30, 2010. Total revenues were $8.1 million for the ... for the three months ended September 30, 2009; revenues in ... of certain excipients used in REMOXY® to King Pharmaceuticals in ...
    ... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a ... tumor specific data to enhance the value of oncology drugs, ... Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as ... 2010. About Champions Biotechnology, Inc. Champions Biotechnology, ...
    Cached Medicine Technology:DURECT Corporation Announces Third Quarter 2010 Financial Results 2DURECT Corporation Announces Third Quarter 2010 Financial Results 3DURECT Corporation Announces Third Quarter 2010 Financial Results 4DURECT Corporation Announces Third Quarter 2010 Financial Results 5DURECT Corporation Announces Third Quarter 2010 Financial Results 6DURECT Corporation Announces Third Quarter 2010 Financial Results 7Champions Biotechnology Awarded $1.46 million in Grants 2
    (Date:8/1/2015)... ... 2015 , ... AlignLife Office Coordinator Heather Pugh earned the position ... patients at this natural health care center in Winamac. , "Oftentimes patients are in ... role is vital to our approach because we want to focus on the patient ...
    (Date:8/1/2015)... ... August 01, 2015 , ... Western University of Health Sciences’ ... comprises a growing percentage of U.S. physicians, and reflects the diversity of the ... of the message delivered by John W. Becher, DO, president of the American ...
    (Date:8/1/2015)... ... 2015 , ... The condition where veins are enlarged and gnarled is known ... and discomfort. Those who spend a lot of time on their feet and standing ... doing what it can to create awareness and provide a cure in observance of ...
    (Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River ... honor by the National Retail Federation, the largest retail trade association in the world, ... Maine business owners to be named as such. According to the NRF’s website, Retail ...
    (Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
    Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
    ... Training physicians in mindfulness meditation and communication skills can ... and their patients, University of Rochester Medical Center researchers ... the journal Academic Medicine . As ways ... a sense of community among physicians and providing time ...
    ... , THURSDAY, April 26 (HealthDay News) -- The ... from 10 a.m. to 2 p.m., the U.S. Drug Enforcement ... safely dispose of unwanted and unused prescription drugs. At ... than 377,000 pounds (188.5 tons) of unwanted or expired medications ...
    ... Thompson HealthDay Reporter , WEDNESDAY, April 25 (HealthDay ... with groups as diverse as the American Cancer Society and ... fragrance as a therapy that can complement traditional health care. ... cure illness, but research has found it can help reduce ...
    ... HealthDay Reporter , WEDNESDAY, April 25 (HealthDay News) ... drugs, their stroke risk goes up quickly, new research ... they are taking warfarin or a newer, more expensive ... heart rhythm in which the upper chambers of the ...
    ... (April 25, 2012) John W. Tsuang, M.D., principal ... Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven ... Medicine, is spearheading a Phase I clinical safety trial ... Ibudilast when administered with metamphetamine (MA), an addictive stimulant ...
    ... Experts are proposing a new model of care ... present with various emergent cardiovascular conditions which require ... of mortality, in an article published April 24 ... as ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, ...
    Cached Medicine News:Health News:Physician's mindfulness skills can improve care for patient and provider 2Health News:Aromatherapy: More Than Just a Pleasant Scent? 2Health News:Aromatherapy: More Than Just a Pleasant Scent? 3Health News:Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat 2Health News:LA BioMed's Dr. John Tsuang examines effects of Ibudilast and metamphetamines 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
    AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
    ... of abuse tests are highly accurate in detecting ... cut-off as confirmed by GC/MS testing. This assay ... alternative method (such as GC/MS) must be used ... judgment should be applied to any drug of ...
    AccuSign® DOA Series Opiates Test...
    ... The QuickScreen™ At Home Drug Test is ... the FDA for home use. The kit includes ... easy to read instructions, a handbook with frequently ... ship the sample to the laboratory if the ...
    Medicine Products: